TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$120 Million

Zafgen, Inc

Follow-on Offering

Bookrunner, January 2015

Zafgen Inc is a US-based biopharmaceutical company. It focuses on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. The lead product candidate of the company is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection. The company operates in the business of developing novel therapeutics. The company primarily carries its business operations in the United States.